Skip to main content
. Author manuscript; available in PMC: 2015 Mar 31.
Published in final edited form as: Annu Rev Virol. 2014 Sep 1;1(1):119–141. doi: 10.1146/annurev-virology-031413-085442

Table 3.

Summary of the oncolytic poxviruses studied in preclinical animal models

Virus name Tumor type(s) Administration route Outcomes Reference(s)
vvDD Pediatric solid tumors IV Inhibited tumor growth; prolonged survival 70
vvDD-A34R M38 peritoneal carcinoma IP More efficient remote virus spread; enhanced efficacy and host survival 87
OVV-CXCR4-A-Fc Murine 4T1 metastatic or orthotopic breast cancer IV Inhibited primary tumor growth and metastatic lesion formation; disrupted tumor vasculature 139
GLV-1h68 Colorectal IV Inhibited tumor growth; elicited inflammation-mediated innate immune response 140
Breast cancer stem-like cells
PC-3 prostate cancer		 Retro-orbital Efficient replication in cancer stem-like cells 141
IV Primary tumor regression; strong inflammatory responses 142
Hepatocellular carcinoma IV Reduced primary tumor size; strong inflammatory responses 143
Bone and soft-tissue sarcoma cells IT Near-complete tumor regression without any observed toxicity 144
Salivary gland carcinoma IT Efficient tumor regression without toxicity 145
Squamous cell carcinoma IT Near-complete tumor regression without any observed toxicity 146
GLV-1h99 Pancreatic cancer/pleural mesothelioma IT/intrapleural Efficient tumor elimination; specific uptake of radiotracer by hNET; allowed deep-tissue imaging using PET 147, 148
GLV-1h108 A549 lung cancer IV Significant enhanced efficacy comparison with GLV-1h68 74
Lung cancer IV Enhanced tumor regression 75
GLV-1h120 A549 lung cancer IV Enhanced oncolytic activity; alleviated cancer-related anemia 86
GLV-1h153 Metastatic or orthotopic triple-negative breast cancer IV/IT Tumor regression; facilitated deep-tissue imaging to identify positive surgical margins 92, 95
Pleural mesothelioma Intrapleural Reduced tumor burden; improved survival; facilitated monitoring by 131I-SPECT/CT 91
Pancreatic cancer IV/IT Tumor regression; NIS-specific radiouptake by cells; facilitated PET imaging 90, 94
Anaplastic thyroid carcinoma IT Oncolytic; potential sensitizer for radiation therapy; facilitated imaging 93
GLV-1h237 Breast cancer IV Enhanced antitumor activity; potential to interfere with host cell DNA synthesis 76
GLV-1h255 PC-3 prostate cancer IT Enhanced tumor regression; facilitated virus spread within tumors by degrading collagen IV 88
GLV-1h285 Glioblastoma primary cancer stem cell lines Intracranial Superior tumor growth control; no recurrence 73
GLV-1h324 A549 lung cancer IT Maintained oncolytic activity; facilitated deep-tissue imaging; provided suitable target for laser-induced thermotherapy 128
vMyx-gfp(tdTr) Acute myeloid leukemia Ex vivoa 90% of mice free of human acute myeloid leukemia in bone marrow 101
Multiple myeloma Ex vivoa All mice free of human multiple myeloma in bone marrow 100
Pancreatic cancer IP Reduced tumor burden; prolonged survival 116
Gliomas IT 92% of mice free of disease 102
Rhabdoid tumors in brain or hind flank IT Reduced tumor size 149
Medulloblastoma IT Prolonged survival 123
Murine melanoma IT Reduced tumor size 110
IV Decreased development of lung metastasis 110
Ex vivoa Prevented tumor implantation 110
MYXV-Fl1L Breast cancer IT Enhanced virus spread to uninjected contralateral tumor 113

Abbreviations: IP, intraperitoneal; IT, intratumoral; IV, intravenous.

a

Ex vivo treatment of transplant sample with myxoma virus prior to engraftment.